Octaplex (Human Coagulation Factor Ix, Protein C, Human Coagulation Factor Vii, Protein S, Human Coagulation F)

The active ingredients are exogenous human coagulation proteins that become part of the patient’s clotting cascade. Once infused, each factor binds to its specific site on activated platelets or endothelial surfaces, restoring the enzymatic steps that convert pro‑thrombin to thrombin and ultimately generate fibrin. This re‑establishes the physiological pathway needed for stable clot formation.

Dosing of Octaplex is individualized. The prescribing clinician determines the amount based on the patient’s specific factor deficiency, severity of bleeding, body weight, and target plasma activity levels. Doses are calculated to achieve therapeutic factor concentrations and are adjusted according to clinical response and laboratory monitoring.

Data on the use of Octaplex during pregnancy and lactation are limited. It should be used only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Healthcare providers should discuss the uncertainties and consider alternative therapies when appropriate.

To order Octaplex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Octaplex is a plasma‑derived, multi‑factor concentrate, whereas many alternatives are single‑factor recombinant products. The multi‑factor composition can be advantageous for patients with combined deficiencies, reducing the need for multiple separate infusions. However, recombinant single‑factor products may carry a lower risk of viral transmission and can be more precisely dosed for isolated deficiencies.

Octaplex must be stored refrigerated at 2‑8 °C. It should be kept in its original container, protected from light, and must not be frozen or shaken. Before use, the product is reconstituted according to the manufacturer’s instructions and administered promptly to maintain stability.

Octaplex is administered by intravenous infusion under medical supervision. After reconstitution, the solution is infused slowly, typically through a peripheral or central line, with vital signs monitored throughout the infusion. The rate and total volume are adjusted based on the prescribed dose and the patient’s clinical condition.

The most serious risks include severe allergic reactions such as anaphylaxis, thromboembolic events (e.g., deep‑vein thrombosis or pulmonary embolism), and the development of neutralizing inhibitors that render the infused factors ineffective. Prompt recognition and management of these events are essential.

Octaplex is contraindicated in individuals with a known hypersensitivity to any human plasma‑derived component of the product. It should also be avoided in patients with active, uncontrolled thrombosis or those in whom the risk of thrombosis outweighs the benefit of factor replacement. Clinical judgment is required for all other cases.